



EY Entrepreneur of the year-2013

FROST & SULLIVAN
Best Practices-2013Business today/YES bank
Excellence Awards-2013**Date: 20 March 2026**

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: PRESS RELEASE**APPLICABLE REGULATION: REGULATION 30 READ WITH PART B(3) OF PARA A OF SCHEDULE III TO THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sir/Madam,

Please find attached a Press Release intended for public dissemination for the launch of generic Semaglutide under the brand 'SUNDAE' in India.

Details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Master circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 are given below:

a.	Name of the product	Semaglutide
b.	Date of launch	21 March 2026
c.	Category of the product	Diabetes treatment
d.	Whether caters to domestic/ international market	Currently for domestic market.
e.	Name of the countries in which the product is launched (in case of international)	Not Applicable

Thanking you.

Yours faithfully,

Eris Lifesciences Limited

Milind

Talegaonkar

r

Digitally signed by
Milind Talegaonkar
Date: 2026.03.20
16:02:52 +05'30'
Milind Talegaonkar**Company Secretary and Compliance Officer****ICSI Membership No.: A26493****Encl: a/a****Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

Eris Brings Breakthrough Diabetes Therapy Within Reach

With Launch of Weekly Shot of Semaglutide Starting at ₹220 Per Shot

Ahmedabad, India – 20th March 2026 - Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, today announced a breakthrough step in expanding access to advanced diabetes care with the launch of its generic Semaglutide under the brand ‘SUNDAE’ in India. Reinforcing its commitment as a responsible stakeholder in addressing the country’s growing diabetes burden, Eris is introducing SUNDAE in multi-dose vial formats at highly accessible pricing starting at Rs 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants. This launch significantly improves affordability, bringing effective GLP-1 therapy within reach for nearly 70% of India’s diabetes patient population. The Company also plans to further enhance patient convenience and adoption with the introduction of a pen-device version in April priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively.



Semaglutide, a GLP-1 receptor agonist, has emerged as a transformative therapy for Type 2 diabetes and weight management, driven by strong outcomes in glycemic control and weight reduction. With India’s rapidly growing diabetic population and rising awareness of obesity, GLP-1 therapies present a significant growth opportunity.

Eris has established a strong presence in diabetology through deep engagement with specialists across India. The addition of semaglutide further strengthens its advanced diabetes portfolio and expands its role in next-generation metabolic care.

ERIS Lifesciences Ltd

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054

Email: investor.relations@eris.co.in; M: +91-79-30451111; CIN: L24232GJ2007PLC049867

The company said: “Semaglutide represents a breakthrough in the management of diabetes and metabolic disorders, with the potential to significantly improve patient outcomes. With the launch of SUNDAE, we are fulfilling our responsibility to make such advanced therapies truly accessible and affordable to a much larger patient population. This reflects our continued commitment to strengthening our diabetes portfolio with high-impact, patient-centric solutions, while leveraging our strong presence in chronic care to drive rapid adoption and expand access across India.

We have been proactively preparing to unlock the GLP-1 opportunity in a meaningful way, and this initiative marks an important step in democratizing access to innovative therapies. We believe it will not only help address the growing diabetes burden in the country but also serve as a key driver of sustainable, long-term value creation for Eris.”

About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS):

Established in 2007, Eris is the youngest among the Top 20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ Cr as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including Oral Solids, Oral Liquids, Softgels, Ointments, Sprays & Gels, Sterile Injectables and Biologics in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.

Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue of INR 2,894 Cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 Cr over the last 3 years.

For Further Details, Please Contact:

Kruti Raval

VP – Investor Relations and M&A
kruti@erislifesciences.com

Atul Modi

Sr. Manager - Investor Relations
atul.modi@eristherapeutics.com

Safe Harbor:

This document includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, allocations of funds by the Governments in the healthcare sector, increasing competition and the conditions of our customers, suppliers and the pharmaceutical industry, global and Indian demand-supply conditions, finished goods prices, cyclical demand and pricing in the company’s principal markets, changes in government laws and regulations, tax regimes, our provisioning policies, economic and political developments within India and the countries within which the company conducts businesses and other factors such as litigation and labour negotiations.

Any forward-looking statement or information contained in this document speaks only as of the date of the statement. The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, based on any subsequent development, information or events or otherwise unless it is required by Law.

ERIS Lifesciences Ltd

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054
Email: investor.relations@eris.co.in; M: +91-79-30451111; CIN: L24232GJ2007PLC049867